Back |
home / stock / sndx / sndx message board
Subject | By | Source | When |
---|---|---|---|
SNDX, $NKTR ink clinical-trial collaboration for Entinostat + | DewDiligence | investorshub | 05/30/2018 9:04:43 PM |
$SNDX ENCORE-601 update | DewDiligence | investorshub | 05/17/2018 1:24:34 PM |
After failure of two high profile IO combination, | tika1 | investorshub | 05/15/2018 2:17:31 AM |
Transcript of $SNDX 1Q18 CC: | DewDiligence | investorshub | 05/10/2018 3:51:33 PM |
$SNDX new investor slide set: | DewDiligence | investorshub | 05/09/2018 8:24:35 PM |
The 1Q18 10-Q has been filed: | DewDiligence | investorshub | 05/09/2018 8:15:20 PM |
$SNDX 1Q18 resultscash=$113M: | DewDiligence | investorshub | 05/08/2018 9:17:20 PM |
$SNDX ASCO lineup: | DewDiligence | investorshub | 04/25/2018 8:38:21 PM |
Yesplease see my reply in #msg-140012720. | DewDiligence | investorshub | 04/13/2018 1:21:06 PM |
Dew, | tika1 | investorshub | 04/13/2018 1:10:07 PM |
$SNDX presentation lineup at AACR: | DewDiligence | investorshub | 04/13/2018 11:56:00 AM |
The annual-report proxy has been filed: | DewDiligence | investorshub | 04/10/2018 8:13:58 PM |
The 2017 10-K has been filed: | DewDiligence | investorshub | 03/08/2018 11:08:00 PM |
SNDX 4Q17 CC slides: | DewDiligence | investorshub | 03/05/2018 9:56:29 PM |
$SNDX 4Q17 results/2018 news-flow12/31/17 cash=$133.2M: | DewDiligence | investorshub | 03/05/2018 9:16:46 PM |
News, Short Squeeze, Breakout and More Instantly...
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress PR Newswire - Data continue to support revumenib's potential to enhance current standard of care agents - ...
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation ...